Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Single Arm-Studies suggest improved remission and survival rates for a Protocol with Mitoxantron 10mg/m2 for 3 days combined with AraC 1g/m2 bid on days 1+3+5+7 compared to a conventional DA 7+3 protocol (45mg/m2 Daunorubicin).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Technische Universität Dresden
• Treatments: Daunorubicin; Mitoxantrone

Criteria

Inclusion Criteria:

• Diagnosis of AML

• age >60

• no previous Chemo for AML

• informed consent

• Karnofsky >70

Exclusion Criteria:

• AML M3

• uncontrolled Sepsis

• uncontrolled HYpertension

• respiratory failure

• heart-failure NYHA IV, recent myocardial infarction

• severe organ dysfunction of liver, kidneys,

• HIV -infection or active Hepatitis B,C